Sustainable Development

The Director Gento Group, Mohamed Gento Kamara has appeal to road users for them to exercise patience with them as they want to do long lasting job. (Photo: Jomo Kenyatta Road)

Gento Group Director was explaining why they failed to meet their deadline of completing the Jomo Kenyatta/King Harman Road junction by end of April.

Giving reasons for not meeting their deadline, Gento Group Director, Mohamed Gento Kamara told this Medium that just after they made the declaration to complete the tarring of that road by April ending, the government asked them to construct a foot bridge along New England Ville junction which he said stalled their timetable for two weeks as they need to draw the plan for that foot bridge and also start the construction.

Meeting / Event Tags:

Training

Meeting

Country / Region Tags:

General Topic Tags:

Sustainable Development

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Gento Group appeal to road users
Log in or register to post comments

Zika vaccine efficacy trials could start in 2017

Wed, 2016-05-04 10:57 — davidmc

By Jon CohenMay. 3, 2016

In the most optimistic scenario, a Zika vaccine could prove its worth by the start of 2018, Anthony Fauci, head of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, said today.

Meeting / Event Tags:

Training

Meeting

Country / Region Tags:

General Topic Tags:

Disaster Risk Reduction

Sustainable Development

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Zika vaccine efficacy trials could start in 2017
Log in or register to post comments

Ebola vaccine: Promising phase I trials

Wed, 2016-05-04 10:51 — davidmc

Date:May 3, 2016Source:German Center for Infection ResearchSummary:The clinical phase I trial of a potential vaccine against the dreaded Ebola virus has been successfully completed at four partner sites in Africa and Europe. The safety of the tested vaccine 'rVSV-ZEBOV', which induces persistent antibodies against the virus, has been confirmed by researchers.

"The results for tolerability, safety, and the immune response to the vaccine candidate are very promising," explains Prof Marylyn Addo. The antibodies which developed against the virus were still detectable after six months. Addo is convinced, "With this, a single vaccine could provide lasting protection against Ebola." The infectious disease specialist, who works for the German Center for Infection Research at the University Medical Center Hamburg Eppendorf (UKE) in Hamburg, led the trial in Hamburg. A total of 158 healthy adult volunteers were tested in Hamburg, as well as at the partner sites in Geneva (Switzerland), Lambaréné; (Gabon) and Kilifi (Kenya).

Meeting / Event Tags:

Meeting

Country / Region Tags:

General Topic Tags:

Disaster Risk Reduction

Sustainable Development

Problem, Solution, SitRep, or ?:

Situation Report

Read more about Ebola vaccine: Promising phase I trials
Log in or register to post comments

Heightened Surveillance: Liberia and Guinea Discharge Ebola Patients

Wed, 2016-05-04 10:46 — davidmc

Monrovia – Liberia’s and Guinea’s last known Ebola patients in a latest flare-up of the disease that hit both countries have now been discharged. All remaining contacts of confirmed cases that were placed under a 3-week period of medical monitoring have been cleared.

Liberia’s Ministry of Health, WHO and partners involved in the response held a ceremony at the Ebola treatment facility in Monrovia to celebrate the recovery and discharge of a 2-year-old boy, the final patient in the flare-up in Liberia.

His 5-year-old brother recovered a week earlier. On 29 April, the country also began a 42-day period of increased surveillance – amounting to two 21-day incubation cycles of the virus.

Meeting / Event Tags:

Training

Meeting

Country / Region Tags:

General Topic Tags:

Disaster Risk Reduction